← Human Trials & Peer-Reviewed Studies
Sequential anti-osteoporotic therapy with teriparatide and alendronate optimizes outcomes of percutaneous vertebroplasty in acute osteoporotic vertebral fractures: a 12-month prospective cohort study
Plain-language guide to PMID 41163205 (2025): observational study study of Teriparatide in 216 women.
Key Facts
- PMID
- 41163205
- Journal
- BMC musculoskeletal disorders
- Year
- 2025
- Study type
- Observational Study
- Authors
- Xie Y et al. (8 authors)
- DOI
- 10.1186/s12891-025-09256-w
What This Study Did, in Plain Language
What Was Tested
This observational study paper looks at Teriparatide.
Previous studies have overlooked the potential impact of anti-osteoporotic medications on PVP outcomes.
Who Took Part
The abstract describes 216 women taking part.
PubMed indexes the participants as middle-aged adults, older adults and people over 80, women only.
In this prospective cohort study, 216 postmenopausal women with fresh OVCFs were allocated to four groups based on patients' preference: ALN monotherapy (ALN group), PVP combined with ALN therapy (ALN + PVP group), sequential therapy with TPTD for 6 months followed by ALN (TPTD group), and PVP combined with sequential TPTD/ALN therapy (TPTD + PVP group).
How the Study Was Run
The timeline in the abstract includes 6 months.
Pain (Visual Analog Scale, VAS), disability (Oswestry Disability Index, ODI), and health-related quality of life (Medical Outcomes Study 36-Item Short Form Health Survey, SF-36) were assessed at 3, 6, and 12 months by one-way ANOVA.
New vertebral fracture incidence was monitored biannually.
What Was Measured
Previous studies have overlooked the potential impact of anti-osteoporotic medications on PVP outcomes.
PubMed files the paper under topics including Alendronate, Bone Density Conservation Agents, Cohort Studies, Fractures, Compression, Osteoporosis, Postmenopausal, Osteoporotic Fractures and Quality of Life.
Author keywords: Osteoporotic vertebral compression fracture, Pain score, Teriparatide and Vertebroplasty.
What This Means in Plain Language
This is a observational study of Teriparatide in 216 women over 6 months.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (BMC musculoskeletal disorders), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.